231 related articles for article (PubMed ID: 31262348)
1. Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a randomized controlled trial.
Kang MG; Kim KI; Ihm SH; Rhee MY; Sohn IS; Lee HY; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Trials; 2019 Jul; 20(1):389. PubMed ID: 31262348
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension.
Lee HY; Kim KI; Ihm SH; Rhee MY; Sohn IS; Park S; Jeon ES; Song JM; Pyun WB; Sung KC; Kim MH; Kim SH; Kim SY; Kim SJ; Kim EJ; Shin J; Lee SY; Chun KJ; Jeong JO; Chae SC; Yoo KD; Choi YJ; Park YH; Kim CH
Clin Ther; 2021 Oct; 43(10):1746-1756. PubMed ID: 34503866
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
[TBL] [Abstract][Full Text] [Related]
6. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
[TBL] [Abstract][Full Text] [Related]
7. FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.
Kim JY; Son JW; Park S; Yoo TH; Kim YJ; Ryu DR; Chin HJ
Trials; 2017 Dec; 18(1):632. PubMed ID: 29284530
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
[TBL] [Abstract][Full Text] [Related]
9. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia.
Rhee MY; Ahn T; Chang K; Chae SC; Yang TH; Shim WJ; Kang TS; Ryu JK; Nah DY; Park TH; Chae IH; Park SW; Lee HY; Tahk SJ; Yoon YW; Shim CY; Shin DG; Seo HS; Lee SY; Kim DI; Kwan J; Joo SJ; Jeong MH; Jeong JO; Sung KC; Kim SY; Kim SH; Chun KJ; Oh DJ
BMC Pharmacol Toxicol; 2017 Jan; 18(1):2. PubMed ID: 28057081
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
Kim KI; Shin MS; Ihm SH; Youn HJ; Sung KC; Chae SC; Nam CW; Seo HS; Park SM; Rhee MY; Kim MH; Cha KS; Kim YJ; Kim JJ; Chun KJ; Yoo BS; Park S; Shin ES; Kim DS; Il Kim D; Kim KH; Joo SJ; Jeong JO; Shin J; Kim CH
Clin Ther; 2016 Oct; 38(10):2159-2170. PubMed ID: 27502326
[TBL] [Abstract][Full Text] [Related]
13. Fimasartan, a novel angiotensin II receptor antagonist.
Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Redon J; Pichler G;
J Hypertens; 2016 Feb; 34(2):359-67. PubMed ID: 26867060
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients.
Chalmers J; Castaigne A; Morgan T; Chastang C
J Hypertens; 2000 Mar; 18(3):327-37. PubMed ID: 10726720
[TBL] [Abstract][Full Text] [Related]
16. Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study).
Chung WB; Ihm SH; Jang SW; Her SH; Park CS; Lee JM; Chang K; Jeon DS; Yoo KD; Seung KB
Drug Des Devel Ther; 2020; 14():347-360. PubMed ID: 32158190
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
Lee HY; Kim YJ; Ahn T; Youn HJ; Chull Chae S; Seog Seo H; Kim KS; Rhee MY; Choi DJ; Kim JJ; Chun KJ; Yoo BS; Park JS; Oh SK; Kim DS; Kwan J; Ahn Y; Bae Park J; Jeong JO; Hyon MS; Cho EJ; Han KR; Kim DI; Joo SJ; Shin JH; Sung KC; Jeon ES
Clin Ther; 2015 Nov; 37(11):2581-2596.e3. PubMed ID: 25850881
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Effect of Fimasartan versus Valsartan on Blood Pressure Variability in Acute Ischemic Stroke: A Double-Blind Randomized Trial.
Shin DH; Song S; Lee YB
Cardiovasc Ther; 2019; 2019():7836527. PubMed ID: 31772615
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
Ruilope LM; Schaefer A
Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
